In:
Mediators of Inflammation, Hindawi Limited, Vol. 12, No. 2 ( 2003), p. 101-105
Abstract:
Background: Platelet-activating factor (PAF) seems to be implicated in systemic lupus erythematosus (SLE) patients with associated renal diseases. Aims: In this study, we ensured the role of PAF in SLE patients without renal complications. Methods: Blood PAF and acetylhydrolase activity, plasma soluble phospholipase A 2 , and the presence of antibodies against PAF were investigated in 17 SLE patients without active nephritis and in 17 healthy controls. Results: Blood PAF levels were not different ( P = 0.45 ) between SLE patients (6.7±2.8 pg/ml) and healthy subjects (9.6±3.1 pg/ml). Plasma acetylhydrolase activity (the PAF-degrading enzyme) was significantly ( P = 0.03 ) elevated in SLE patients (57.8±6.4 nmol/min/ml) as compared with controls (37.9±2.6 nmol/min/ml). Plasma soluble phospholipase A 2 (the key enzyme for PAF formation) was not different ( P = 0.6 ) between SLE patients (59.1±5.1 U/ml) and controls (54.7±2.4 U/ml). Antibodies against PAF were detected only in 3/17 SLE patients. Flow cytometry analysis did not highlight PAF receptors on circulating leukocytes of SLE patients. Conclusion: This clinical study highlights no evidence for a putative important role of PAF in SLE patients without active nephritis.
Type of Medium:
Online Resource
ISSN:
0962-9351
,
1466-1861
DOI:
10.1080/0962935031000097718
Language:
English
Publisher:
Hindawi Limited
Publication Date:
2003
detail.hit.zdb_id:
2008065-7
Permalink